Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25075
Title: Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.
Authors: 
Keywords: 
Issue Date: 2016
Citation: Clinicoecon Outcomes Res.2016;(8):475-484
Abstract: To evaluate the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and with comorbidities that make them unsuitable for full-dose fludarabine-based therapy, from the perspective of the Spanish National Health System.
PMID: 27703384
URI: https://hdl.handle.net/20.500.12530/25075
Rights: openAccess
ISSN: 1178-6981
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos

Files in This Item:
File Description SizeFormat 
PMC5036824.pdf929.65 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.